文献速递湿疹皮炎与荨麻疹

五国慢性自发性荨麻疹的患病率、治疗与疾病负担

Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-06-05

基于2020年EU5国家健康与健康调查数据,评估慢性自发性荨麻疹(CSU)在法国、德国、意大利、西班牙和英国的患病率、治疗模式及疾病负担。EU5加权患病率为0.92%,约半数患者使用处方和/或非处方药物,71.6%疾病控制不佳,36.7%的患者DLQI>10,且焦虑、抑郁及工作效率影响显著。

要点

  • EU5成人CSU加权患病率为0.92%。
  • 71.6%的CSU患者疾病控制不佳,36.7%的患者DLQI>10。
  • CSU患者心理及生活质量评分差于一般人群,英国焦虑抑郁及工作效率影响最高。

核心结论

  • CSU对患者生活产生负面影响,但许多患者治疗不足且疾病未控制,需要综合护理方法改善结局。

研究设计与样本

  • 数据来自2020年EU5国家健康与健康调查(NHWS),共62,319名受访者,其中794例诊断为慢性荨麻疹,519例为CSU。
  • 按年龄和性别调整估计EU5总体及各国的CSU患病率,并描述CSU队列的社会人口学、健康特征、治疗史及皮肤病特异性生活质量。
  • 患者报告结局包括SF-12v2(MCS、PCS)、SF-6D、EQ-5D、GAD-7、PHQ-9、WPAI及医疗资源使用(HRU),与全NHWS样本进行描述性比较。

主要发现

  • EU5 CSU加权患病率为0.92%。
  • 约半数CSU队列接受处方和/或非处方药物治疗。
  • 36.7%的CSU患者经历非常大至极大的疾病影响(DLQI>10),71.6%的患者疾病控制不佳。
  • CSU队列的平均MCS、PCS、SF-6D和EQ-5D评分均差于全NHWS样本。
  • CSU队列中GAD-7和PHQ-9评分≥5的比例高于全NHWS样本;轻度至重度焦虑、抑郁及WPAI评分在英国最高;HRU高于全NHWS样本。

临床怎么用

  • 临床应关注CSU患者疾病控制情况,多数患者控制不佳,需优化治疗。
  • 评估CSU患者时应同时关注生活质量、焦虑抑郁及工作效率影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although chronic spontaneous urticaria (CSU) is a common form of chronic urticaria (CU), its impact on overall disease burden and treatment patterns in real-world settings requires further understanding. OBJECTIVES: To assess prevalence, treatment patterns, disease profile and burden in patients with CSU in five European countries (EU5: France, Germany, Italy, Spain and the United Kingdom [UK]). METHODS: Data were from the 2020 EU5 National Health and Wellness Survey (NHWS). Age- and sex-adjusted prevalence of diagnosed CSU was estimated for the overall EU5 and by country. Sociodemographic, health characteristics, treatment history and dermatology-specific quality of life were described for the CSU cohort. Patient-reported outcomes, including the Short Form 12-item Survey (SF-12v2) mental (MCS), physical component (PCS) summary scores; SF-6D; EQ-5D; General Anxiety Disorder-7 (GAD-7); Patient Health Questionnaire-9 (PHQ-9); Work Productivity and Activity Impairment (WPAI) and healthcare resource use (HRU), were summarized for the CSU cohort, overall and by country and descriptively compared to the full NHWS sample. RESULTS: Of 62,319 respondents, 794 patients were diagnosed with CU. Among these, 519 had CSU. Weighted prevalence of CSU in EU5 was 0.92%. Roughly half of the CSU cohort was treated with prescription and/or over-the-counter medication. Among the CSU cohort, 36.7% of patients experienced a very large to extremely large disease impact (Dermatology Life Quality Index [DLQI] > 10); most had poorly controlled disease (71.6%). Mean MCS, PCS, SF-6D and EQ-5D scores were worse for CSU versus the full NHWS sample. A higher proportion of the CSU cohort, versus the full NHWS sample, had GAD-7 and PHQ-9 scores of ≥5. Mild-severe anxiety, depression and WPAI scores were highest in the UK. HRU was higher in the CSU cohort than in the full NHWS sample. CONCLUSIONS: CSU negatively impacts patients' lives. Yet, many patients remain inadequately treated and uncontrolled. These results highlight a need for comprehensive care approaches to improve patient outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Balp MM, Krupsky K, Gupta S, et al. Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries. J Eur Acad Dermatol Venereol. 2025. PMID: 40474558. doi:10.1111/jdv.20772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。